CureVac N.V.

Total Valuation

CureVac N.V. carries a market capitalization of 879.52M, placing it among publicly traded companies globally. Its enterprise value stands at 641.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

CureVac N.V. currently has 225.17M shares outstanding.

Valuation Ratios

CureVac N.V. trades at a trailing price-to-earnings ratio of 7.96. The price-to-sales ratio is 14.50, and the price-to-book ratio stands at -0.84.

Enterprise Valuation

On an enterprise value basis, CureVac N.V. trades at an EV/EBITDA multiple of 3.76 and an EV/FCF ratio of 4.32. The EV/Sales ratio of 9.07 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.20 provides insight into valuation relative to core operating earnings.

Financial Position

CureVac N.V. maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.02, indicating elevated leverage, while an interest coverage ratio of 27.57 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, CureVac N.V. has paid 28.57M in income taxes, reflecting an effective tax rate of 18.15.

Stock Price Statistics

CureVac N.V.'s stock has gained approximately 12.24138% over the past 52 weeks. The 50-day moving average sits at 4.22, while the 200-day moving average is 4.16.

Income Statement

Over the trailing twelve months, CureVac N.V. generated 70.74M in revenue and converted that into 128.82M in net income, yielding earnings per share of 0.57. EBITDA reached 170.40M, while operating income came in at 152.75M.

Balance Sheet

CureVac N.V. holds 419.21M in cash and equivalents against 35.07M in total debt, resulting in a net debt position of -416.09M. Total book value stands at -1.22B, with working capital of 636.94M providing operational flexibility.

Cash Flow

CureVac N.V. produced -120.14M in operating cash flow over the past twelve months. After subtracting -4.96M in capital expenditures, free cash flow totaled -125.09M - equivalent to -0.56 per share.

Margins

CureVac N.V. operates with a gross margin of 93.00, reflecting its pricing power and cost economics. The operating margin of 215.93 and net profit margin of 182.11 provide insight into operational efficiency.

Dividends & Yields

Scores

CureVac N.V. posts an Altman Z-Score of 1.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.